Drug Discovery World

NOVEMBER 16, 2023

Casgevy (exagamglogene autotemcel, or exa-cel) is the first medicine to be licensed that uses gene editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. To date, a bone marrow transplant – which must come from a closely matched donor and carries a risk of rejection – has been the only permanent treatment option.

Therapies 277

Therapies Clinical Trials Trials Treatment 277

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Discovery World

JULY 12, 2024

AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of Parkinson’s disease.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).

Trials 299

Trials Drugs Clinical Trials Licensing 299

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

JULY 2, 2024

City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a Phase II/III trial to assess the novel use of CBM588 and microbiome modulation in people with advanced cancer.

Trials 147

Trials Treatment Clinical Trials Licensing 147

Drug Discovery World

MARCH 7, 2024

A combined pipeline of therapeutic candidates Akari’s nomacopan is a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4) being evaluated in a Phase III clinical trial for paediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147

Drug Discovery World

MARCH 13, 2024

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. Across JNJ-2113 treatment groups, 58.6% at 16 weeks and 76.2% at 52 weeks).

Trials 130

Trials Clinical Trials Treatment Licensing 130

Drug Discovery World

DECEMBER 20, 2022

The CHMP has recommended conditional marketing authorisation of CSL’s (etranacogene dezaparvovec), a one-time gene therapy for the treatment of appropriate adults with the disease. . A one-time treatment with etranacogene dezaparvovec costs US$3.5 The therapy was also recently approved by the FDA for patients in the US. .

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

JULY 28, 2023

The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. New eBook: Breakthroughs accelerating therapeutic antibodies The latest eBook by DDW is out now.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Conversations in Drug Development Trends

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

The Pharma Data

JANUARY 3, 2021

United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application. With these important regulatory clearances for our first-in-human clinical trial for INZ-701 in subjects with ENPP1 deficiency, we have transitioned from a research-stage to a clinical-stage company.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

Drug Discovery World

MARCH 6, 2024

Earlier last year the biotech successfully led a second round of investment, taking the total up to £13.2m ($16.7m), which will take it up to the start of in-human clinical trials later this year. SynaptixBio has signed a worldwide exclusive license to intellectual property from CHOP, enabling commercialisation of a treatment​.

FDA 130

FDA Disease Therapies Drugs 130

Drug Discovery World

JANUARY 30, 2024

Natalia Elizalde, Chief Business Development Officer, VIVEbiotech, says that Dr Naldini’s award represents the significant benefits and demonstrated safety of the therapies developed using lentiviral vectors that are being used for more and more clinical trials and more prevalent diseases.

Therapies 179

Therapies Clinical Trials Trials Production 179

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. We hope that this EP4-targeting approach will deliver a promising route to improving treatment options for patients with a broad range of cancers.”

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

FEBRUARY 27, 2023

Destiny Pharma is obliged to continue its current plan to complete the ongoing manufacture of all clinical trial supplies needed to undertake the required clinical studies. NTCD-M3 acts as a safe ‘ground cover’, preventing toxic strains of C difficile proliferating in the colon after antibiotic treatment.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. Under the terms of the agreement, ImaginAb will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials. LOS ANGELES , Jan.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

APRIL 5, 2023

The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, London. NXP800 has been licensed to oncology-focused biopharmaceutical company Nuvectis Pharma, which is leading the further development.

Clinical Trials 130

Clinical Trials Pharmacokinetics Drugs DNA 130

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. The drugs are currently approved as treatments for type 2 diabetes and weight loss.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

Drug Discovery World

DECEMBER 2, 2022

The US Food and Drug Administration (FDA) has accepted Sarepta Therapeutics’ Biologics License Application (BLA) seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy. .

FDA 130

FDA Therapies Clinical Trials Licensing 130

The Pharma Data

OCTOBER 19, 2020

(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company’s U.S. About CNS Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

DrugBank

AUGUST 15, 2024

This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks. Their established infrastructure, including access to patient populations and clinical trial sites, can significantly accelerate the development timeline.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio intend to continue a Phase IIb clinical trial in 2024 in the United States, Europe, and Japan. Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD. of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. .

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

JANUARY 17, 2023

Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early AD. .

FDA 130

FDA Clinical Trials Licensing Licensing 130

Drug Discovery World

APRIL 6, 2023

The recommendation will grant patients in England and Wales with early-stage, high-risk breast cancer and inherited mutations in BRCA1 or BRCA2 access to olaparib following standard treatment. NICE previously decided not to recommend the drug as a prostate cancer treatment due to the high cost of genetic testing.

Clinical Trials 130

Clinical Trials Licensing Licensing Treatment 130

Drug Discovery World

OCTOBER 12, 2022

Why are digital biomarkers important in clinical trials? . Collecting objective data with sensors as part of a clinical trial not only helps verify the subjective data collected from patients and investigators, it also provides data gathered more often and in the patient’s natural setting (compared to a clinical setting).

Clinical Trials 130

Clinical Trials Trials Disease Clinical Research 130